The combined assessment of PB IL-6 and FLT3-ligand levels during AML induction therapy revealed that patients with persistent high IL‐6 levels display lower survival rates compared to patients with decreasing IL-6 and increasing FLT3-ligand levels (134). Here, IL6 is linked to acute myeloid leukemia.